Vaginal atrophy. Postmenopausal atrophic vaginitis
Conditions
Interventions
Intervention 1: Control group: The control group used one-fifth of an applicator (one gram) of vaginal cream every night for six weeks and in the next two weeks every other night. At the end of the 4
Sponsors
Gonabad University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
45 Years to 65 Years
Inclusion criteria
Inclusion criteria: Age between 45 and 65 years 1 to 2 years have passed since menopause Having at least a degree with reading and writing literacy Having informed consent to participate in the research Married and monogamous No history of pelvic surgery (according to the participant's statement) Non-use of drugs and alcohol in the woman and her husband (according to the participant's statement) Not taking estrogenic drugs Absence of vaginal bleeding No history of radiation therapy or chemotherapy of the pelvis or the whole body No cancer No history of infertility (according to the participant's statement) Absence of spouse suffering from premature ejaculation or impotence (according to the participant's statement) Absence of vaginal infections (based on the participants' statements and questions about the clinical symptoms of vaginitis) Not suffering from psychological disorders such as: psychosis, schizophrenia, delusions, etc. (according to the participant himself) Having at least 2 symptoms from the descriptive evaluation table of the vaginal mucosa (color, roughness, petechiae, elasticity, dryness) Obtaining a score of 23 or less according to the Sexual Performance Index (FSFI) questionnaire Not having diabetes (according to the participant's statement)
Exclusion criteria
Exclusion criteria: Allergy to cumin vaginal cream Taking any medication affecting sexual performance during the study Starting to take hormonal drugs during the study Experiencing unfortunate or stressful events in a woman or her husband Dissatisfaction to continue cooperation in research Absence of diseases in women or their spouses that affect sexual performance (such as premature ejaculation, cardiovascular, mental, thyroid and cancers) Getting stressed (such as divorce, infidelity of a spouse, death of loved ones in the last year, serious illnesses or imprisonment)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vaginal atrophy. Timepoint: Before, 4 and 8 weeks after the intervention. Method of measurement: Descriptive assessment of vaginal mucosa.;Sexual function. Timepoint: Before, 4 and 8 weeks after the intervention. Method of measurement: Female Sexual Function Index.;Women's sexual distress. Timepoint: Before, 4 and 8 weeks after the intervention. Method of measurement: Female Sexual Distress Scal.;Vaginal atrophy daily effects. Timepoint: Before, 4 and 8 weeks after the intervention. Method of measurement: Vaginal atrophy daily effects questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFatemeh kermani
Gonabad University of Medical Sciences
Outcome results
None listed